Lyell Immunopharma, Inc.
At Close: 4:00 PM
LYEL Stock Price Graph
LYEL Stock Price Today
Lyell Immunopharma, Inc. (LYEL) stock rallied over 2.13% intraday to trade at $1.92 a share on NASDAQ. The stock opened with a loss of -14.95% at $1.65 and touched an intraday high of $1.65, falling -1.03% against the last close of $1.94. The Lyell Immunopharma, Inc. in stock market went to a low of $1.57 during the session.
LYEL Stock Snapshot
Number of Shares
Cash Flow per Share
Free Float in %
LYEL Stock Price History Chart
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Frequently Asked Questions
What is the current Lyell Immunopharma, Inc. (LYEL) stock price?
Lyell Immunopharma, Inc. (NASDAQ: LYEL) stock price is $1.92 in the last trading session. During the trading session, LYEL stock reached the peak price of $1.65 while $1.57 was the lowest point it dropped to. The percentage change in LYEL stock occurred in the recent session was 2.13% while the dollar amount for the price change in LYEL stock was $0.04.
LYEL's industry and sector of operation?
The NASDAQ listed LYEL is part of Biotechnology industry that operates in the broader Healthcare sector. Lyell Immunopharma, Inc. , a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors.
Who are the executives of LYEL?
Ms. Elizabeth Homans
Chief Executive Officer & Director
Dr. Lynn Seely M.D., Ph.D.
Pres, Chief Executive Officer & Director
Vice President of Communications & Investor Relations
Mr. Richard Goold Ph.D.
Chief Information Officer
How LYEL did perform over past 52-week?
LYEL's closing price is 0.37% higher than its 52-week low of $1.32 where as its distance from 52-week high of $6.18 is -0.72%.
How many employees does LYEL have?
Number of LYEL employees currently stands at N/A. LYEL operates from 201 Haskins Way, South San Francisco, CA 94080, US.
Link for LYEL official website?
Official Website of LYEL is: https://www.lyell.com
How do I contact LYEL?
How many shares of LYEL are traded daily?
LYEL stock volume for the day was 862109.00 shares. The average number of LYEL shares traded daily for last 3 months was 920.81 Thousands.
What is the market cap of LYEL currently?
The market value of LYEL currently stands at $483.59 Million with its latest stock price at $1.92 and N/A of its shares outstanding.